Elon Musk’s Neuralink has raised $650 million to continue advancing its brain implants for patients with paralysis and other disorders, the company said.
The series E funding round included such investors as ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed, QIA, Sequoia Capital, Thrive Capital, Valor Equity Partners, Vy Capital, according to a June 2 blog post.
Neuralink has secured FDA Breakthrough Device Designation for vision and speech restoration, and is currently conducting clinical trials at Phoenix-based Barrow Neurological Institute, The Miami Project to Cure Paralysis at the University of Miami, University Health Network (Toronto Western Hospital), and Cleveland Clinic Abu Dhabi.
